An Eagle Eye on AQUILA Survival Data. Our New Paper Is Out. IQWiG Wins, OpenEvidence Fails.

Our new paper, with Sunny Kim and Vinay Prasad, is out in the Journal of Cancer Policy and is openly available here! Not all patients with Smoldering…

Apr 14 • Timothée Olivier

14

1

The Chinese Immunotherapy That Passed the Dutch Test, and How To Assess What is Expected to Be a Tsunami of Immunotherapies.

The Dutch are rather picky in selecting which oncology drugs to prescribe or reimburse.

Apr 12 • Sahar van Waalwijk and Timothée Olivier

22

3

March 2026

An outstanding source of trial data lacking from publications: IQWiG assessment reports. The NIAGARA trial example.

Reports from HTA bodies may contain key data absent from trial publications and constitute a unique source for trial appraisal.

Mar 25 • Timothée Olivier

13

2

1

My IQWiG lecture in Cologne! What a great audience and team!

I was invited by IQWiG to give a lecture in Cologne, Germany. The talk was followed by fascinating discussions with the IQWiG team about methodology in…

Mar 23 • Timothée Olivier

12

49:29

The BREAKING-ICE App© V2.0 is out! Enjoy automated explorations and a new companion KM digitizer App.

Discover “Automated” modes. Discover the brand-new, user-friendly, Assistant-KM-BREAKING-ICE© app, which allows you to extract and directly explore data…

Mar 21 • Timothée Olivier

14

1

The Imbalance of NCCN Guidelines: Quick to Implement, Slow to Let Go

It’s my great pleasure to welcome Christopher Rios to The Oncology Shot.

Mar 9 • Christopher Rios

16

1

1

February 2026

Critical Appraisal in Breast Cancer: The Essentials in 30 Minutes.

Here is a live recording of a talk I gave at SAMO on 27 February 2026.

Feb 28 • Timothée Olivier

15

1

33:54

The PATINA trial – palbociclib maintenance in metastatic breast cancer.

What is the best 1st-line strategy in patients with HR+/HER2+ advanced/metastatic breast cancer?

Feb 8 • Timothée Olivier

16

4

January 2026

The puzzle of PARP inhibitors plus ARPI in Prostate Cancer: 12 mutations, 3 trials, and 5 different labels.

In a new paper just published in eClinicalMedicine, part of the Lancet group, we discuss, together with Sahar van Waalwijk, the fascinating consequences…

Jan 22 • Hans Westgeest and Timothée Olivier

17

2

December 2025

Aging Out of Evidence: Why Cancer Trials Still Miss Older Adults

There is a need for trials mirroring real-world practices.

Dec 24, 2025 • Alyson Haslam

20

1

How To Study Drugs With Apparent Massive Effect Sizes, Still Using Randomization?

We proposed a trial design to answer this question.

Dec 16, 2025 • Timothée Olivier

18

3

2

Placebo First, Treatment Later: Is This Fair to Patients With Active Cancer?

In a new paper, we examined the randomized trials using inert control arms (mostly placebo only) leading to FDA approvals.

Dec 14, 2025 • Timothée Olivier

19

4